Last reviewed · How we verify

Dyspepsia Prevention — Treatment Landscape & Competitive Intelligence

Dyspepsia Prevention (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Dyspepsia Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Pepcid famotidine Generic (originally Yamanouchi/Merck) Histamine-2 Receptor Antagonist [EPC] Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2 1986-10-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Generic (originally Yamanouchi/Merck) · 1 drug in Dyspepsia Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Dyspepsia Prevention:

Cite this brief

Drug Landscape (2026). Dyspepsia Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/dyspepsia-prevention. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing